Toripalimab
- Generic Name
- Toripalimab
- Brand Names
- Loqtorzi
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1924598-82-2
- Unique Ingredient Identifier
- 8JXN261VVA
- Background
Toripalimab is under investigation in clinical trial NCT03919383 (Phase II of Lenvatinib Plus Toripalimab for Advanced HCC).
- Indication
⑴用于治疗既往标准治疗失败后的局部进展或转移性黑色素瘤。⑵用于治疗既往接受过二线及以上系统治疗失败的复发/转移性鼻咽癌（NPC）。⑶用于治疗既往接受过治疗的局部进展或转移性尿路上皮癌（UC）。⑷用于食管鳞癌一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Toripalimab Combined With Definitive CCRT for LACC Patients
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06256224
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial
- Conditions
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
- Target Recruit Count
- 30
- Registration Number
- NCT06256237
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China
Toripalimab Therapy After Resection in High-risk Stage IA2-IB NSCLC With no Driver Alterations (EGFR or ALK)
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Target Recruit Count
- 51
- Registration Number
- NCT06221670
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-01-17
- Target Recruit Count
- 268
- Registration Number
- NCT06208826
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
- Conditions
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 200
- Registration Number
- NCT06201065
- Locations
- 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China
Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007)
- Conditions
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 140
- Registration Number
- NCT06187597
- Locations
- 🇨🇳
Mian Xi, Guangzhou, Guangdong, China
DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06178159
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06155383
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Shandong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
- Target Recruit Count
- 186
- Registration Number
- NCT06139211
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Toripalimab Combined with Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT06127303
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China
🇨🇳Zhongshan Hospital, Fudan University, Shanghai, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.